Literature DB >> 18562636

AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome.

Erin S R Lashinger1, Matthew S Steiginga, J Paul Hieble, Lisa A Leon, Scott D Gardner, Rakesh Nagilla, Elizabeth A Davenport, Bryan E Hoffman, Nicholas J Laping, Xin Su.   

Abstract

The activation of the TRPM8 channel, a member of the large class of TRP ion channels, has been reported to be involved in overactive bladder and painful bladder syndrome, although an endogenous activator has not been identified. In this study, N-(3-aminopropyl)-2-{[(3-methylphenyl) methyl]oxy}-N-(2-thienylmethyl)benzamide hydrochloride salt (AMTB) was evaluated as a TRPM8 channel blocker and used as a tool to evaluate the effects of this class of ion channel blocker on volume-induced bladder contraction and nociceptive reflex responses to noxious bladder distension in the rat. AMTB inhibits icilin-induced TRPM8 channel activation as measured in a Ca(2+) influx assay, with a pIC(50) of 6.23. In the anesthetized rat, intravenous administration of AMTB (3 mg/kg) decreased the frequency of volume-induced bladder contractions, without reducing the amplitude of contraction. The nociceptive response was measured by analyzing both visceromotor reflex (VMR) and cardiovascular (pressor) responses to urinary bladder distension (UBD) under 1% isoflurane. AMTB (10 mg/kg) significantly attenuated reflex responses to noxious UBD to 5.42 and 56.51% of the maximal VMR response and pressor response, respectively. The ID50 value on VMR response was 2.42 +/- 0.46 mg/kg. These results demonstrate that TRPM8 channel blocker can act on the bladder afferent pathway to attenuate the bladder micturition reflex and nociceptive reflex responses in the rat. Targeting TRPM8 channel may provide a new therapeutic opportunity for overactive bladder and painful bladder syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562636     DOI: 10.1152/ajprenal.90269.2008

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  55 in total

Review 1.  From urgency to frequency: facts and controversies of TRPs in the lower urinary tract.

Authors:  Roman Skryma; Natalia Prevarskaya; Dimitra Gkika; Yaroslav Shuba
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

Review 2.  Pharmacology of transient receptor potential melastatin channels in the vasculature.

Authors:  Alexander Zholos
Journal:  Br J Pharmacol       Date:  2010-03-05       Impact factor: 8.739

Review 3.  Regulation of TRPM8 channel activity.

Authors:  Yevgen Yudin; Tibor Rohacs
Journal:  Mol Cell Endocrinol       Date:  2011-10-28       Impact factor: 4.102

Review 4.  Transient receptor potential (TRP) channels: a clinical perspective.

Authors:  Yosuke Kaneko; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

5.  Strategies for therapeutic hypometabothermia.

Authors:  Shimin Liu; Jiang-Fan Chen
Journal:  J Exp Stroke Transl Med       Date:  2012-01-01

Review 6.  TRPM8 and Migraine.

Authors:  Greg Dussor; Yu-Qing Cao
Journal:  Headache       Date:  2016-09-16       Impact factor: 5.887

7.  Enhanced insulin clearance in mice lacking TRPM8 channels.

Authors:  Daniel D McCoy; Ligang Zhou; Anh-Khoi Nguyen; Alan G Watts; Casey M Donovan; David D McKemy
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-07       Impact factor: 4.310

Review 8.  Transient receptor potential channels as therapeutic targets.

Authors:  Magdalene M Moran; Michael Allen McAlexander; Tamás Bíró; Arpad Szallasi
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

Review 9.  Scraping through the ice: uncovering the role of TRPM8 in cold transduction.

Authors:  Daniel D McCoy; Wendy M Knowlton; David D McKemy
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-03-16       Impact factor: 3.619

Review 10.  Calcium influx pathways in breast cancer: opportunities for pharmacological intervention.

Authors:  I Azimi; S J Roberts-Thomson; G R Monteith
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.